Literature DB >> 26794303

Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease.

Erin M Johnson1, Mark Roberts2, Tahseen Mozaffar3, Peter Young4, Adrian Quartel5, Kenneth I Berger6.   

Abstract

In patients with Late-Onset Pompe Disease (LOPD), progressive respiratory muscle involvement leads to reduced pulmonary function, with respiratory failure the most common cause of mortality. Early disease manifestations include sleep-disordered breathing, which can be treated with non-invasive ventilation; however, progressive diurnal deficits can require invasive ventilation. To determine if pulmonary function tests (PFTs) predict the thresholds for ventilation and wheelchair use, a systematic literature review identified cross-sectional clinical patient data (N = 174) that was classified into ventilation and wheelchair cohorts. PFTs included maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), forced vital capacity (FVC), and vital capacity (VC), with vital capacities measured in the upright (-U) and supine (-S) positions. Receiver operating characteristic (ROC) curves were used to calculate cut-points (CP) and area under the curve (AUC). For all ventilation and mobility thresholds tested, ROC analyses demonstrated AUC values from 86-89% for MIP, 72-96% for MEP, and 74-96% for all vital capacity metrics. Thus, PFTs are useful in predicting the thresholds for nighttime ventilation, daytime ventilation, and wheelchair use, with MIP and VC-U having both high AUC values and consistency. The PFT mobility CPs were low (MIP CP = 0.9 kPa, MEP, CP = 2.6 kPa, VC-U CP = 19% predicted), suggesting an endurance component associated with wheelchair use.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inspiratory pressure; Late-Onset Pompe disease; Ventilation; Ventilator; Vital capacity; Wheelchair test

Mesh:

Year:  2015        PMID: 26794303     DOI: 10.1016/j.nmd.2015.11.009

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

Review 1.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  A multi-trial, retrospective analysis of the antihypertensive effects of high-resistance, low-volume inspiratory muscle strength training.

Authors:  Daniel H Craighead; Dallin Tavoian; Kaitlin A Freeberg; Josie L Mazzone; Jennifer R Vranish; Claire M DeLucia; Douglas R Seals; E Fiona Bailey
Journal:  J Appl Physiol (1985)       Date:  2022-09-15

3.  Effect of Test Interface on Respiratory Muscle Activity and Pulmonary Function During Respiratory Testing in Healthy Adults: A Pilot Study.

Authors:  Elaheh Sajjadi; Patrick C Mabe; Yasin B Seven; Barbara K Smith
Journal:  Cardiopulm Phys Ther J       Date:  2022-04

4.  Sleep-Disordered Breathing and Effects of Noninvasive Ventilation in Patients with Late-Onset Pompe Disease.

Authors:  Matthias Boentert; Bianca Dräger; Christian Glatz; Peter Young
Journal:  J Clin Sleep Med       Date:  2016-12-15       Impact factor: 4.062

5.  Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series.

Authors:  Mai K ElMallah; Ankit K Desai; Erica B Nading; Stephanie DeArmey; Richard M Kravitz; Priya S Kishnani
Journal:  Pediatr Pulmonol       Date:  2020-01-03

Review 6.  Practical Recommendations for Diagnosis and Management of Respiratory Muscle Weakness in Late-Onset Pompe Disease.

Authors:  Matthias Boentert; Hélène Prigent; Katalin Várdi; Harrison N Jones; Uwe Mellies; Anita K Simonds; Stephan Wenninger; Emilia Barrot Cortés; Marco Confalonieri
Journal:  Int J Mol Sci       Date:  2016-10-17       Impact factor: 5.923

7.  A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.

Authors:  Barry J Byrne; Tarekegn Geberhiwot; Bruce A Barshop; Richard Barohn; Derralynn Hughes; Drago Bratkovic; Claude Desnuelle; Pascal Laforet; Eugen Mengel; Mark Roberts; Peter Haroldsen; Kristin Reilley; Kala Jayaram; Ke Yang; Liron Walsh
Journal:  Orphanet J Rare Dis       Date:  2017-08-24       Impact factor: 4.123

8.  A case of unexplained dyspnoea: when lung function testing matters!

Authors:  Pierantonio Laveneziana; Marie-Cécile Niérat; Antonella LoMauro; Andrea Aliverti
Journal:  Breathe (Sheff)       Date:  2018-12

9.  Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.

Authors:  David W Stockton; Priya Kishnani; Ans van der Ploeg; Juan Llerena; Matthias Boentert; Mark Roberts; Barry J Byrne; Roberto Araujo; Sonia S Maruti; Nathan Thibault; Karien Verhulst; Kenneth I Berger
Journal:  J Neurol       Date:  2020-06-10       Impact factor: 4.849

10.  Deoxynucleoside therapy for respiratory involvement in adult patients with thymidine kinase 2-deficient myopathy.

Authors:  Ana Hernandez-Voth; Javier Sayas Catalan; Marta Corral Blanco; Alba Castaño Mendez; Miguel Angel Martin; Carlos De Fuenmayor Fernandez de la Hoz; Victoria Villena Garrido; Cristina Dominguez-Gonzalez
Journal:  BMJ Open Respir Res       Date:  2020-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.